Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-05-31 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Isan Chen, M.D. 37,336,370 541,765 3,109,065 Gilla Kaplan, Ph.D. 37,581,968 296,167 3,109,065 Robert More 37,571,418 306,717 3,109,065
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 40,984,756 625 1,819 0
View on SEC.gov